Annual report [Section 13 and 15(d), not S-K Item 405]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)

v3.25.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Product Information [Line Items]    
Cash, uninsured amount $ 100,000 $ 100,000
Cash equivalents 0 0
Inventory valuation reserves 9,000,000.0 9,500,000
Advertising expense $ 500,000 1,200,000
Amount of tax benefits percent 85.00%  
Amount of tax benefits remaining percent 15.00%  
Liability for returns included in accrued expenses $ 100,000 100,000
Liabilities related to refunds 0  
VAT payable $ 400,000 $ 400,000
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Two Customer [Member]    
Product Information [Line Items]    
Concentration Risk, Percentage 32.00%  
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | One Customer [Member]    
Product Information [Line Items]    
Concentration Risk, Percentage 21.00%  
Customer Concentration Risk [Member] | Accounts Receivable [Member] | No Customer [Member]    
Product Information [Line Items]    
Concentration Risk, Percentage 5.00%  
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Customer One [Member]    
Product Information [Line Items]    
Concentration Risk, Percentage   11.00%
IPO [Member] | Minimum [Member] | Airgraft Inc [Member]    
Product Information [Line Items]    
Total order cost, percentage 25.00%  
IPO [Member] | Maximum [Member] | Airgraft Inc [Member]    
Product Information [Line Items]    
Total order cost, percentage 50.00%